May 2005
Volume 46, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2005
F200, a Fab Derivative of M200 (Volociximab; Anti–A5ß1), Is a Potent Inhibitor of Angiogenesis in a Rabbit Model of Choroidal Neovascularization
Author Affiliations & Notes
  • V. Ramakrishnan
    Dir Antibody Development, Chief of the Retina Service,
    Protein Design Labs Inc, Fremont, CA
  • B.D. Kuppermann
    Dir Antibody Development, Chief of the Retina Service,
    UC Irvine, Irvine, CA
  • V. Bhaskar
    Staff Scientist, Antibody Development, Research Fellow,
    Protein Design Labs Inc, Fremont, CA
  • P. Wales
    Research Associate, Antibody Development,
    Protein Design Labs Inc, Fremont, CA
  • L.F. Hagemann
    Staff Scientist, Antibody Development, Research Fellow,
    UC Irvine, Irvine, CA
  • L. Marques
    Research Associate, Antibody Development,
    UC Irvine, Irvine, CA
  • R.P. de Carvalho
    Wilmer Eye Institute, Johns Hopkins University, Baltimore, MD
  • C.G. Wong
    SCLERA LLC, Laguna Beach, CA
  • R. Murray
    Chief Scientific Officer,
    Protein Design Labs Inc, Fremont, CA
  • Footnotes
    Commercial Relationships  V. Ramakrishnan, Protein Design Labs, Inc E, P; B.D. Kuppermann, Protein Design Labs., Inc C; V. Bhaskar, Protein Design labs., Inc E; P. Wales, Protein Design Labs., Inc E; L.F. Hagemann, Protein Design Labs, Inc F; L. Marques, Protein Design Labs., Inc F; R.P. de Carvalho, Protein Design Labs, Inc F, R; C.G. Wong, Protein Design Labs, Inc C, R; R. Murray, Protein Design Labs., Inc E.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2005, Vol.46, 465. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      V. Ramakrishnan, B.D. Kuppermann, V. Bhaskar, P. Wales, L.F. Hagemann, L. Marques, R.P. de Carvalho, C.G. Wong, R. Murray; F200, a Fab Derivative of M200 (Volociximab; Anti–A5ß1), Is a Potent Inhibitor of Angiogenesis in a Rabbit Model of Choroidal Neovascularization . Invest. Ophthalmol. Vis. Sci. 2005;46(13):465.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: To evaluate anti–α5ß1 antibodies in a rabbit model of sub–retinal choroidal neovascularization (CNV). Methods: Adult Dutch pigmented rabbits were implanted suprachroidally on Day 0 with either VEGF/bFGF Hydron® pellets or blank pellets. Animals were assessed by fundus photography (FP) and fluorescein angiography (FAs) at weeks 1,2,3,4, and 8. Clinical grading of FP and FA was performed by two masked graders on a 0–4 scale. Animals were sacrificed and enucleated at week 4 and week 8 for histology. In 2 separate experiments, F200 and M200 were assessed for (a) inhibition of sub–retinal CNV (b) efficacy of M200 administered I.V. (c) efficacy of a single dose of F200 and (d) efficacy of F200 administered as a treatment modality . Results: F200 and M200 are potent inhibitors of laser–induced CNV in the cynomolgus monkey model (ARVO 2003). In this report, F200 and M200 were tested in a novel rabbit model in which the development of CNV is progressive and appears primarily beneath the intact retina. We found that CNV develops in ∼40–70% of the eyes of animals implanted with the growth factor pellet, as assessed by FP and FA. F200 and M200 administered intravitreally or M200 administered I.V. at the time of pellet implantation (D0) and D15, suppressed the development of CNV to undetectable levels by week 4, unlike animals dosed with vehicle. F200 strongly inhibited the development of CNV in animals administered at D0 with a single high dose of drug, and this effect persisted for 8 weeks. Additionally, CNV was also significantly inhibited in animals treated with F200 one week after pellet implantation. No safety related issues were noted with M200 or F200. Conclusions: Anti–α5ß1 integrin antibodies M200 and F200 are potent inhibitors of in the rabbit model of sub–retinal CNV, showing significant activity when administered intravitreally or I.V. at the time of implant. Additionally, our data suggests that F200 inhibits CNV when administered in a therapeutic mode, and therefore these agents have potential for the treatment of age–related macular degeneration.

Keywords: age-related macular degeneration • receptors • clinical research methodology 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×